跳转至内容
Merck
CN

926345

Sigma-Aldrich

NanoFabTx™-DC-Chol Lipid Mix

for synthesis of cationic (DC-cholesterol) liposomes

登录查看公司和协议定价

选择尺寸

关于此项目

UNSPSC代码:
12162002
NACRES:
NA.23

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

一般描述

NanoFabTx™-DC-Chol Lipid Mix; for synthesis of cationic (DC-cholesterol) liposomes is a ready-to-use nanoformulation blend for the synthesis of liposomes for drug delivery. The NanoFabTx™-DC-Chol Lipid Mix includes optimized protocols with step-by-step instructions for synthesizing cationic DC-cholesterol liposomes for drug delivery applications. The modification of the liposomes with the cationic lipid, DC-cholesterol, have numerous advantages including high gene transfection efficiency. Liposome-based formulations are widely used for drug delivery applications and enable improved therapeutic efficacy of a range of drug types including small molecules, nucleic acids, proteins, and peptides.

应用

About NanoFabTx™

NanoFabTx™ lipid mixes and formulation kits enable users to encapsulate a wide variety of therapuetic drug molecules for targeted or extended drug delivery without the need for lengthy trial-and-error optimization. NanoFabTx™ reagent kits provide an easy-to-use toolkit for encapsulating a variety of therapeutics in nanoparticles, microparticles, or liposomes. Drug encapsulated particles synthesized with the NanoFabTx™ kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery.

特点和优势

  • A ready-to-use nanoformulation blend for the synthesis of cationic DC-cholesterol liposomes
  • Step-by-step protocols (extrusion or microfluidic) developed and tested by our formulation scientists
  • Flexible synthesis tools to create uniform and reproducible liposomes
  • Optimized to make liposomes around 100 nm with low polydispersity
  • DC-Cholesterol allows for high transfection efficiency and targeted drug delivery
Comprehensive protocols for liposome synthesis are included:
  • A lipid film hydration and extrusion protocol.
  • A microfluidics protocol using commercial platforms or syringe pumps.
The microfluidics protocol included with this product uses the NanoFabTx™ device kit (911593). These kits are ready-to-use and include the microfluidic chip, fittings, and tubing required for microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

法律信息

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

储存分类代码

11 - Combustible Solids

WGK

WGK 3

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
MKCR1808

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients.
Mayer LD, et al.
Biochimica et Biophysica Acta, 1025, 143-151 (1990)
Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications
Panahi Y, et al.
Artificial Cells, Nanomedicine, and Biotechnology (Print), 45, 788-799 (2017)
Which polymers can make nanoparticulate drug carriers long-circulating?
Torchilin VP, et al.
Advanced Drug Delivery Reviews, 16, 141?155-141?155 (1995)
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy
Papahadjopoulos D, et al.
Proceedings of the National Academy of Sciences of the USA, 88, 11460-11464 (1991)
T D Madden et al.
Chemistry and physics of lipids, 53(1), 37-46 (1990-03-01)
We have shown previously that transmembrane proton gradients can be used to efficiently accumulate biogenic amines [M.B. Bally et al. (1988) Chem. Phys. Lipids 47, 97-107] and doxorubicin [L.D. Mayer, M.B. Bally and P.R. Cullis (1986) Biochim. Biophys. Acta 857
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持